The application value of 6-minute walking test in clinical evaluation of chronic heart failure_Chinese Journal of Evidence-Based Medicine

Authors：

HOU Yazhu ^1,2 ^# , YAN Lingyan ³ ^# ,  MAO Jingyuan ^1,2 , WANG Xianliang ^1,2 , LI Ling ⁴ , ZHONG Chengliang ⁵ , LIU Hanwen ^1,2 , ZHAO Zhiqiang ^1,2

1. Department of Cardiology, the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, P.R.China;
2. National Clinical Research Base of Traditional Chinese Medicine for Coronary Heart Disease, Tianjin, 300193, P.R.China;
3. Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, P.R.China;
4. The Chinese Cochrane Center, West China Hospital, Chengdu, 610041, P.R.China;
5. Medical Statistics Room, First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, P.R.China;

Corresponding?author：

MAO Jingyuan, Email: jymao@126.com

Keywords：

6-minute walking test; 6-minute walking distance; Chronic heart failure; Consistency; Influencing factor; Randomized controlled trial

DOI：

10.7507/1672-2531.201804092

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

ObjectivesTo analyze the application value of 6-minute walking test (6MWT) in the clinical evaluation of chronic heart failure (CHF).MethodsPubMed, EMbase, The Cochrane Library, CBM, VIP, WanFang Data and CNKI databases were searched online to collect randomized controlled trials (RCTs) of 6-minute walking distance (6MWD) as the CHF evaluation index. Two reviewers independently screened literature, extracted data, and then analyzed data by using SPSS 17.0 statistical software. The 6MWD with symptom, quality of life, exercise tolerance (ETT), left ventricular ejection fraction (LVEF), peak oxygen consumption (pVO₂) were analyzed by Kappa consistency test, and the possible influencing factors of 6MWD were analyzed by logistic regression.ResultsA total of 158 RCTs involving 17 853 patients were included. The results of statistical analysis showed that: 6MWD was consistent with the improvement of symptoms, quality of life, ETT, LVEF and pVO₂ (Kappa>0.4). Baseline 6MWD (OR=2.91, 95%CI 1.278 to 6.634,P=0.011) and NYHA Ⅲ-Ⅳ ratio (OR=2.59, 95%CI 1.091 to 6.138, P=0.031) were the independent influencing factors for 6MWD improvement separately.ConclusionsThe 6MWT is an objective and reliable indicator of CHF evaluation.

Citation： HOU Yazhu, YAN Lingyan, MAO Jingyuan, WANG Xianliang, LI Ling, ZHONG Chengliang, LIU Hanwen, ZHAO Zhiqiang. The application value of 6-minute walking test in clinical evaluation of chronic heart failure. Chinese Journal of Evidence-Based Medicine, 2018, 18(9): 907-917. doi: 10.7507/1672-2531.201804092 Copy

1.	European Society of Cardiology. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J, 2016: 1-85.
2.	Lalonde F. Guidelines for cardiac rehabilitation and secondary prevention programs. J Am Osteopath Assoc NLM, 2012, 11: 753-754.
3.	ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med, 2002, 166(1): 111-117.
4.	Cahalin L, Pappagianopoulos P, Prevost S, et al. The relationship of the 6-min walk test to maximal oxygen consumption in transplant candidates with end-stage lung disease. Chest, 1995, 108(2): 452-459.
5.	Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation, 2013, 128(16): 240-327.
6.	McMurray JJV, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Eur Heart J, 2012, 33(14): 1787-1847.
7.	徐勇勇. 醫學統計學(第2版). 北京: 高等教育出版社, 2004: 234-236.
8.	Bristow MR, O'Connell JB, Gilbert EM, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. Circulation, 1994, 89(4): 1632-1642.
9.	Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation, 1995, 92(2): 212-218.
10.	Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation, 1995, 92(6): 1499-1506.
11.	Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective randomized evaluation of carvedilol on symptoms and exercise. Circulation, 1996, 94(11): 2793-2799.
12.	Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation, 1996, 94(11): 2807-2816.
13.	Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet, 1997, 349(9049): 375-380.
14.	Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure. J Card Fail, 1997, 3(3): 173-179.
15.	Khand AU, Rankin AC, Martin W, et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol, 2003, 42(11): 1944-1951.
16.	Sanderson JE, Chan SK, Yip G, et al. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol, 1999, 34(5): 1522-1528.
17.	Metra M, Giubbini R, Nodari S, et al. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation, 2000, 102(5): 546-551.
18.	Sanderson JE, Chan SK, Yu CM, et al. Beta blockers in heart failure: a comparison of a vasodilating beta blocker with metoprolol. Heart, 1998, 79(1): 86-92.
19.	Genth-Zotz S, Zotz RJ, Sigmund M, et al. MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing. Eur J Heart Fail, 2000, 2(2): 175-181.
20.	Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation, 2000, 101(4): 378-384.
21.	Beanlands RS, Nahmias C, Gordon E, et al. The effects of beta(1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: A double-blind, placebo-controlled, positron-emission tomography study. Circulation, 2000, 102(17): 2070-2075.
22.	de Milliano PA, de Groot AC, Tijssen JG, et al. Beneficial effects of metoprolol on myocardial sympathetic function: Evidence from a randomized, placebo-controlled study in patients with congestive heart failure. Am Heart J, 2002, 144(2): E3.
23.	包志宏, 韓盈, 盛梓松. 充血性心力衰竭患者心功能及運動耐量與卡維地洛的干預. 中國臨床康復, 2005, (15): 53-55.
24.	黃良順, 劉克強. 比較卡維地洛與酒石酸美托洛爾治療慢性心力衰竭的療效. 中外健康文摘, 2013, 29: 89-90.
25.	Barabino A, Galbariggi G, Pizzorni C, et al. Comparative effects of long-term therapy with captopril and ibopamine in chronic congestive heart failure in old patients. Cardiology, 1991, 78(3): 243-256.
26.	Cowley AJ, McEntegart DJ, Hampton JR, et al. Long-term evaluation of treatment for chronic heart failure: a 1 year comparative trial of flosequinan and captopril. Cardiovasc Drugs Ther, 1994, 8(6): 829-836.
27.	Comparison of the effects of cilazapril and captopril versus placebo on exercise testing in chronic heart failure patients: a double-blind, randomized, multicenter trial. Cardiology, 1995, 86(supply 1): 34-40.
28.	Beynon JH, Pathy MS. An open, parallel group comparison of quinapril and captopril, when added to diuretic therapy, in the treatment of elderly patients with heart failure. Curr Med Res Opin, 1997, 13(10): 583-592.
29.	Hutcheon SD, Gillespie ND, Crombie IK, et al. Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: a randomised double blind placebo controlled trial. Heart, 2002, 88(4): 373-377.
30.	Zi M, Carmichael N, Lye M. The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovasc Drugs Ther, 2003, 17(2): 133-139.
31.	Kitzman DW, Hundley WG, Brubaker PH, et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circ Heart Fail, 2010, 3(4): 477-485.
32.	Dickstein K, Chang P, Willenheimer R, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol, 1995, 26(2): 438-445.
33.	Lang RM, Elkayam U, Yellen LG, et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. J Am Coll Cardiol, 1997, 30(4): 983-991.
34.	McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation, 1999, 100(10): 1056-1064.
35.	Granger CB, Ertl G, Kuch J, et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J, 2000, 139(4): 609-617.
36.	Willenheimer R, Helmers C, Pantev E, et al. Safety and efficacy of valsartan versus enalapril in heart failure patients. Int J Cardiol, 2002, 85(2-3): 261-270.
37.	李旭豐, 崔紅玉, 楊靜. 纈沙坦治療慢性充血性心力衰竭療效觀察. 中國心血管雜志, 2002, 7(1): 41-43.
38.	黃祖敏, 梁昌強, 王瑞烈, 等. 厄貝沙坦對缺血性心肌病伴慢性心功不全患者六分鐘步行試驗的影響. 遵義醫學院學報, 2004, (5): 464-465.
39.	李漢成. 貝那普利治療慢性充血性心力衰竭療效觀察. 中國熱帶醫學, 2008, (10): 1770-1774.
40.	施亞明, 宗永忠, 紀敏, 等. 纈沙坦和貝那普利對糖尿病心肌病患者六分鐘步行試驗的影響. 臨床醫學, 2009, (12): 11-12.
41.	Kurrelmeyer KM, Ashton Y, Xu J, et al. Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. J Card Fail, 2014, 20(8): 560-568.
42.	Van Kraaij DJ, Jansen RW, Bouwels LH, et al. Furosemide withdrawal in elderly heart failure patients with preserved left ventricular systolic function. Am J Cardiol, 2000, 85(12): 1461-1466.
43.	賈芳, 黃銳, 鄭僑克, 等. 托拉塞米與呋塞米治療老年慢性心力衰竭伴利尿劑抵抗的短期療效觀察. 中國傷殘醫學, 2013, 21(10): 33-35.
44.	Guyatt GH, Sullivan MJ, Fallen EL, et al. A controlled trial of digoxin in congestive heart failure. Am J Cardiol, 1988, 61(4): 371-375.
45.	Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol, 1993, 22(4): 955-962.
46.	Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med, 1993, 329(1): 1-7.
47.	Lader E, Egan D, Hunsberger S, et al. The effect of digoxin on the quality of life in patients with heart failure. J Card Fail, 2003, 9(1): 4-12.
48.	Benatar D, Hall V, Reddy S, et al. Clinical and neurohormonal effects of nicardipine hydrochloride in patients with severe chronic heart failure receiving angiotensin-converting enzyme inhibitor therapy. Am J Ther, 1998, 5(1): 25-32.
49.	Udelson JE, DeAbate CA, Berk M, et al. Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. Am Heart J, 2000, 139(3): 503-510.
50.	肖杰, 顧曄, 成忠, 等. 維拉帕米對左室舒張期心力衰竭患者的療效觀察. 中國醫院藥學雜志, 2010, (16): 1377-1379.
51.	Laufs U, Wassmann S, Schackmann S, et al. Beneficial effects of statins in patients with non-ischemic heart failure. Z Kardiol, 2004, 93(2): 103-108.
52.	李繼遠. 辛伐他汀對慢性心力衰竭患者心功能和運動耐量的影響. 實用全科醫學, 2007, (10): 869-870.
53.	Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med, 2001, 344(12): 873-880.
54.	Auricchio A, Stellbrink C, Sack S, et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol, 2002, 39(12): 2026-2033.
55.	Leclercq C, Walker S, Linde C, et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J, 2002, 23(22): 1780-1787.
56.	Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med, 2002, 346(24): 1845-1853.
57.	Varma C, Sharma S, Firoozi S, et al. Atriobiventricular pacing improves exercise capacity in patients with heart failure and intraventricular conduction delay. J Am Coll Cardiol, 2003, 41(4): 582-588.
58.	Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA, 2003, 289(20): 2685-2694.
59.	Garrigue S, Bordachar P, Reuter S, et al. Comparison of permanent left ventricular and biventricular pacing in patients with heart failure and chronic atrial fibrillation: a prospective hemodynamic study. Card Electrophysiol Rev, 2003, 7(4): 315-324.
60.	Auricchio A, Stellbrink C, Butter C, et al. Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. J Am Coll Cardiol, 2003, 42(12): 2109-2116.
61.	Higgins SL, Hummel JD, Niazi IK, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol, 2003, 42(8): 1454-1459.
62.	Abraham WT, Young JB, León AR, et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation, 2004, 110(18): 2864-2868.
63.	Gasparini M, Bocchiardo M, Lunati M, et al. Comparison of 1-year effects of left ventricular and biventricular pacing in patients with heart failure who have ventricular arrhythmias and left bundle-branch block: the Bi vs Left Ventricular Pacing: an International Pilot Evaluation on Heart Failure Patients with Ventricular Arrhythmias (BELIEVE) multicenter prospective randomized pilot study. Am Heart J, 2006, 152(1): 155. e1-e7.
64.	Chung ES, Menon SG, Weiss R, et al. Feasibility of biventricular pacing in patients with recent myocardial infarction: impact on ventricular remodeling. Congest Heart Fail, 2007, 13(1): 9-15.
65.	Rao K, Fisher ML, Robinson S, et al. Effect of chronic changes in heart rate on congestive heart failure. J Card Fail, 2007, 13(4): 269-274.
66.	Goscinska-Bis K, Bis J, Krejca M, et al. Totally epicardial cardiac resynchronization therapy system implantation in patients with heart failure undergoing CABG. Eur J Heart Fail, 2008, 10(5): 498-506.
67.	Orlov MV, Gardin JM, Slawsky M, et al. Biventricular pacing improves cardiac function and prevents further left atrial remodeling in patients with symptomatic atrial fibrillation after atrioventricular node ablation. Am Heart J, 2010, 159(2): 264-270.
68.	Sims DB, Mignatti A, Colombo PC, et al. Rate responsive pacing using cardiac resynchronization therapy in patients with chronotropic incompetence and chronic heart failure. Europace, 2011, 13(10): 1459-1463.
69.	Thibault B, Ducharme A, Harel F, et al. Left ventricular versus simultaneous biventricular pacing in patients with heart failure and a QRS complex≥120 milliseconds. Circulation, 2011, 124(25): 2874-2881.
70.	Di Molfetta A, Forleo GB, Santini L, et al. A novel methodology for AV and VV delay optimization in CRT: results from a randomized pilot clinical trial. J Artif Organs, 2013, 16(3): 273-283.
71.	Rampengan SH, Prihartono J, Siagian M, et al. The effect of enhanced external counterpulsation therapy and improvement of functional capacity in chronic heart failure patients: a randomized clinical trial. Acta Med Indones, 2015, 47(4): 275-282.
72.	Meyer K, Schwaibold M, Westbrook S, et al. Effects of exercise training and activity restriction on 6-minute walking test performance in patients with chronic heart failure. Am Heart J, 1997, 133(4): 447-453.
73.	McKelvie RS, Teo KK, Roberts R, et al. Effects of exercise training in patients with heart failure: the Exercise Rehabilitation Trial (EXERT). Am Heart J, 2002, 144(1): 23-30.
74.	Giannuzzi P, Temporelli PL, Corrà U, et al. Antiremodeling effect of long-term exercise training in patients with stable chronic heart failure: results of the Exercise in Left Ventricular Dysfunction and Chronic Heart Failure (ELVD-CHF) Trial. Circulation, 2003, 108(5): 554-559.
75.	Gary RA, Sueta CA, Dougherty M, et al. Home-based exercise improves functional performance and quality of life in women with diastolic heart failure. Heart Lung, 2004, 33(4): 210-218.
76.	Corvera-Tindel T, Doering LV, Woo MA, et al. Effects of a home walking exercise program on functional status and symptoms in heart failure. Am Heart J, 2004, 147(2): 339-346.
77.	成蓓, 張秀娥, 彭雯. 運動訓練方案對慢性心力衰竭患者運動耐量和心功能的影響(英文). 中國臨床康復, 2005, 9(23): 241-243.
78.	Brodie DA, Inoue A. Motivational interviewing to promote physical activity for people with chronic heart failure. J Adv Nurs, 2005, 50(5): 518-527.
79.	Oka RK, Sanders MG. The impact of exercise on body composition and nutritional intake in patients with heart failure. Prog Cardiovasc Nurs, 2005, 20(4): 148-154.
80.	Dracup K, Evangelista LS, Hamilton MA, et al. Effects of a home-based exercise program on clinical outcomes in heart failure. Am Heart J, 2007, 154(5): 877-883.
81.	Witham MD, Argo IS, Johnston DW, et al. Long-term follow-up of very old heart failure patients enrolled in a trial of exercise training. Am J Geriatr Cardiol, 2007, 16(4): 243-248.
82.	Karavidas A, Parissis J, Arapi S, et al. Effects of functional electrical stimulation on quality of life and emotional stress in patients with chronic heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy: a randomised, placebo-controlled trial. Eur J Heart Fail, 2008, 10(7): 709-713.
83.	Butterfield JA, Faddy SC, Davidson P, et al. Exercise training in patients with stable chronic heart failure: effects on thoracic impedance cardiography and B-type natriuretic peptide. J Cardiopulm Rehabil Prev, 2008, 28(1): 33-37.
84.	Nilsson BB, Westheim A, Risberg MA. Effects of group-based high-intensity aerobic interval training in patients with chronic heart failure. Am J Cardiol, 2008, 102(10): 1361-1365.
85.	Palevo G, Keteyian SJ, Kang M, et al. Resistance exercise training improves heart function and physical fitness in stable patients with heart failure. J Cardiopulm Rehabil Prev, 2009, 29(5): 294-298.
86.	Winkelmann ER, Chiappa GR, Lima CO, et al. Addition of inspiratory muscle training to aerobic training improves cardiorespiratory responses to exercise in patients with heart failure and inspiratory muscle weakness. Am Heart J, 2009, 158(5): 768. e1-e7.
87.	Brubaker PH, Moore JB, Stewart KP, et al. Endurance exercise training in older patients with heart failure: results from a randomized, controlled, single-blind trial. J Am Geriatr Soc, 2009, 57(11): 1982-1989.
88.	Karapolat H, Demir E, Bozkaya YT, et al. Comparison of hospital-based versus home-based exercise training in patients with heart failure: effects on functional capacity, quality of life, psychological symptoms, and hemodynamic parameters. Clin Res Cardiol, 2009, 98(10): 635-642.
89.	Nilsson BB, Westheim A, Risberg MA, et al. No effect of group-based aerobic interval training on N-terminal pro- B-type natriuretic peptide levels in patients with chronic heart failure. Scand Cardiovasc J, 2010, 44(4): 223-229.
90.	Caminiti G, Volterrani M, Marazzi G, et al. Tai chi enhances the effects of endurance training in the rehabilitation of elderly patients with chronic heart failure. Rehabil Res Pract, 2011, 2011: 761958.
91.	Yeh GY, McCarthy EP, Wayne PM, et al. Tai chi exercise in patients with chronic heart failure: a randomized clinical trial. Arch Intern Med, 2011, 171(8): 750-757.
92.	Keast ML, Slovinec D'Angelo ME, Nelson CR, et al. Randomized trial of Nordic walking in patients with moderate to severe heart failure. Can J Cardiol, 2013, 29(11): 1470-1476.
93.	Borland M, Rosenkvist A, Cider. A group-based exercise programme did not improve physical activity in patients with chronic heart failure and comorbidity:a randomized controlled trial. J Rehabil Med, 2014, 46: 461-67.
94.	Palau P, Domínguez E, Nú?ez E, et al. Effects of inspiratory muscle training in patients with heart failure with preserved ejection fraction. Eur J Prev Cardiol, 2014, 21(12): 1465-1473.
95.	Piotrowicz E, Zieliński T, Bodalski R, et al. Home-based telemonitored Nordic walking training is well accepted, safe, effective and has high adherence among heart failure patients, including those with cardiovascular implantable electronic devices: a randomised controlled study. Eur J Prev Cardiol, 2015, 22(11): 1368-1377.
96.	Vordos Z, Kouidi E, Mavrovouniotis F, et al. Impact of traditional Greek dancing on jumping ability, muscular strength and lower limb endurance in cardiac rehabilitation programmes. Eur J Cardiovasc Nurs, 2017, 16(2): 150-156.
97.	Antonicelli R, Spazzafumo L, Scalvini S, et al. Exercise: a "new drug" for elderly patients with chronic heart failure. Aging (Albany NY), 2016, 8(5): 860-872.
98.	彭雯, 張秀娥, 成蓓. 6分鐘步行試驗在老年慢性心衰患者康復中的應用. 中國康復醫學雜志, 2003, 18(4): 32-34.
99.	趙孝君. 運動訓練改善老年慢性心力衰竭患者的心功能和運動耐力. 中國臨床康復, 2005, (16): 170-171.
100.	Li X, Zhang J, Huang J, et al. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. J Am Coll Cardiol, 2013, 62(12): 1065-1072.
101.	何柳平, 吳玉付. 芪參益氣滴丸治療慢性充血性心力衰竭竇性心律震蕩的臨床研究. 天津中醫藥, 2009, 26(3): 202-204.
102.	安炎霞, 張群生, 丁智曉. 芪參益氣滴丸治療冠心病心力衰竭的臨床觀察. 實用心腦肺血管病雜志, 2010, (3): 367-368.
103.	陳協興, 葉明芳. 燈盞生脈膠囊對慢性心力衰竭患者心功能及運動耐量的影響. 中外婦兒健康, 2011, (8): 286.
104.	何懷陽, 容超. 固本救心方治療男性重癥心力衰竭的臨床研究及對血清睪酮的影響. 時珍國醫國藥, 2013, 24(4): 835-836.
105.	王永剛, 鐘偉, 于遠望, 等. 參附芎澤膠囊治療慢性心力衰竭59例臨床觀察. 中醫雜志, 2013, 54(3): 218-221.
106.	袁萌楠, 賈銀明. 芪藶強心膠囊治療慢性心力衰竭療效觀察. 廣西中醫藥, 2014, 37(5): 12-14.
107.	Sueta CA, Gheorghiade M, Adams KF Jr, et al. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group. Am J Cardiol, 1995, 75(3): 34A-43A.
108.	Rector TS, Bank AJ, Mullen KA, et al. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation, 1996, 93(12): 2135-2141.
109.	Osterziel KJ, Strohm O, Schuler J, et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet, 1998, 351(9111): 1233-1237.
110.	Oliva F, Latini R, Politi A, et al. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J, 1999, 138(2 Pt 1): 247-253.
111.	Deswal A, Bozkurt B, Seta Y, et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation, 1999, 99(25): 3224-3226.
112.	Artinian NT, Harden JK, Kronenberg MW, et al. Pilot study of a Web-based compliance monitoring device for patients with congestive heart failure. Heart Lung, 2003, 32(4): 226-233.
113.	Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation, 2003, 107(2): 294-299.
114.	Zeng XH, Zeng XJ, Li YY. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol, 2003, 92(2): 173-176.
115.	Galbreath AD, Krasuski RA, Smith B, et al. Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure. Circulation, 2004, 110(23): 3518-3526.
116.	Witte KK, Nikitin NP, Parker AC, et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J, 2005, 26(21): 2238-2244.
117.	Torre-Amione G, Sestier F, Radovancevic B, et al. Broad modulation of tissue responses (immune activation) by celacade may favorably influence pathologic processes associated with heart failure progression. Am J Cardiol, 2005, 95(11A): 30C-37C.
118.	Gong K, Zhang Z, Sun X, et al. The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure. Am Heart J, 2006, 151(1): 62-68.
119.	Gavin AD, Struthers AD. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart, 2005, 91(6): 749-753.
120.	Bradley TD, Logan AG, Kimoff RJ, et al. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med, 2005, 353(19): 2025-2033.
121.	Beck-da-Silva L, Higginson L, Fraser M, et al. Effect of Orlistat in obese patients with heart failure: a pilot study. Congest Heart Fail, 2005, 11(3): 118-123.
122.	Palazzuoli A, Silverberg D, Iovine F, et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J, 2006, 152(6): 1096.
123.	Cingolani HE, Plastino JA, Escudero EM, et al. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study. J Card Fail, 2006, 12(7): 491-498.
124.	Neelagaru SB, Sanchez JE, Lau SK, et al. Nonexcitatory, cardiac contractility modulation electrical impulses: feasibility study for advanced heart failure in patients with normal QRS duration. Heart Rhythm, 2006, 3(10): 1140-1147.
125.	Jug B, Sebestjen M, Sabovic M, et al. Clopidogrel is associated with a lesser increase in NT-proBNP when compared to aspirin in patients with ischemic heart failure. J Card Fail, 2006, 12(6): 446-451.
126.	Kumar A, Singh RB, Saxena M, et al. Effect of carni Q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the Tishcon study. Acta Cardiol, 2007, 62(4): 349-354.
127.	Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation, 2007, 116(14): 1555-1562.
128.	Di Napoli P, Di Giovanni P, Gaeta MA, et al. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial. J Cardiovasc Pharmacol, 2007, 50(5): 585-589.
129.	Kourea K, Parissis JT, Farmakis D, et al. Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil, 2008, 15(3): 365-369.
130.	Parissis JT, Kourea K, Panou F, et al. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J, 2008, 155(4): 751. e1-e7.
131.	Khan MN, Ja?s P, Cummings J, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med, 2008, 359(17): 1778-1785.
132.	Bakan G, Akyol AD. Theory-guided interventions for adaptation to heart failure. J Adv Nurs, 2008, 61(6): 596-608.
133.	Kanoksilp A, Hengrussamee K, Wuthiwaropas P. A comparison of one-year outcome in adult patients with heart failure in two medical setting: heart failure clinic and daily physician practice. J Med Assoc Thai, 2009, 92(4): 466-470.
134.	Moreira DM, Vieira JL, Gottschall CA. The effects of METhotrexate therapy on the physical capacity of patients with ISchemic heart failure: a randomized double-blind, placebo-controlled trial (METIS trial). J Card Fail, 2009, 15(10): 828-834.
135.	Evangelista LS, Heber D, Li Z, et al. Reduced body weight and adiposity with a high-protein diet improves functional status, lipid profiles, glycemic control, and quality of life in patients with heart failure: a feasibility study. J Cardiovasc Nurs, 2009, 24(3): 207-215.
136.	Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med, 2009, 361(25): 2436-2448.
137.	Shelton RJ, Clark AL, Goode K, et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart, 2009, 95(11): 924-930.
138.	Swanson KS, Gevirtz RN, Brown M, et al. The effect of biofeedback on function in patients with heart failure. Appl Psychophysiol Biofeedback, 2009, 34(2): 71-91.
139.	Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol, 2009, 54(10): 919-927.
140.	Iellamo F, Volterrani M, Caminiti G, et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol, 2010, 56(16): 1310-1316.
141.	Witham MD, Crighton LJ, Gillespie ND, et al. The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: a randomized controlled trial. Circ Heart Fail, 2010, 3(2): 195-201.
142.	Giles TD, Elkayam U, Bhattacharya M, et al. Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease. Congest Heart Fail, 2010, 16(3): 111-117.
143.	Povsic TJ, O'Connor CM, Henry T, et al. A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction. Am Heart J, 2011, 162(4): 654-662.
144.	Duckers HJ, Houtgraaf J, Hehrlein C, et al. Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial. EuroIntervention, 2011, 6(7): 805-812.
145.	Caminiti G, Volterrani M, Marazzi G, et al. Hydrotherapy added to endurance training versus endurance training alone in elderly patients with chronic heart failure: a randomized pilot study. Int J Cardiol, 2011, 148(2): 199-203.
146.	Carvalho AP, Rassi S, Fontana KE, et al. Influence of creatine supplementation on the functional capacity of patients with heart failure. Arq Bras Cardiol, 2012, 99(1): 623-629.
147.	Costanzo MR, Heywood JT, Massie BM, et al. A double-blind, randomized, parallel, placebo-controlled study examining the effect of cross-linked polyelectrolyte in heart failure patients with chronic kidney disease. Eur J Heart Fail, 2012, 14(8): 922-930.
148.	Bussoni MF, Guirado GN, Matsubara LS, et al. Diastolic function and functional capacity after a single session of continuous positive airway pressure in patients with compensated heart failure. Clinics (Sao Paulo), 2014, 69(5): 354-359.
149.	Vullaganti S, Goldsmith J, Teruya S, et al. Cardiovascular effects of hemoglobin response in patients receiving epoetin alfa and oral iron in heart failure with a preserved ejection fraction. J Geriatr Cardiol, 2014, 11(2): 100-105.
150.	Winter JL, Castro PF, Quintana JC, et al. Effects of trimetazidine in non-ischemic heart failure: A randomized study. J Card Fail, 2014, 20(3): 149-154.
151.	Dunbar SB, Reilly CM, Gary R, et al. Randomized clinical trial of an integrated self-care intervention for persons with heart failure and diabetes: quality of life and physical functioning outcomes. J Card Fail, 2015, 21(9): 719-729.
152.	Athilingam P, Edwards JD, Valdes EG, et al. Computerized auditory cognitive training to improve cognition and functional outcomes in patients with heart failure: Results of a pilot study. Heart Lung, 2015, 44(2): 120-128.
153.	Anker SD, Coats AJ, Cristian G, et al. A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial). Eur Heart J, 2015, 36(34): 2297-2309.
154.	Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J, 2015, 36(11): 657-668.
155.	van Riet EE, Hoes AW, Limburg A, et al. Effect of training general practitioners in drug treatment of newly detected heart failure patients with reduced or preserved ejection fraction: A cluster randomized trial. Int J Cardiol, 2016, 217: 174-182.
156.	Maulik SK, Wilson V, Seth S, et al. Clinical efficacy of water extract of stem bark of Terminalia arjuna (Roxb. ex DC.) Wight & Arn. in patients of chronic heart failure: a double-blind, randomized controlled trial. Phytomedicine, 2016, 23(11): 1211-1219.
157.	Domenichini G, Rahneva T, Diab IG, et al. The lung impedance monitoring in treatment of chronic heart failure (the LIMIT-CHF study). Europace, 2016, 18(3): 428-435.
158.	Bublitz C, Renno AC, Ramos RS, et al. Acute effects of low-level laser therapy irradiation on blood lactate and muscle fatigue perception in hospitalized patients with heart failure-a pilot study. Lasers Med Sci, 2016, 31(6): 1203-1209.
159.	李兢, 莊漢屏, 劉麗華. 曲美他嗪輔助治療老年人充血性心力衰竭的臨床觀察. 實用心腦肺血管病雜志, 2004, 12(3): 129-132.
160.	曹曉菁, 李艷芳, 曹芳芳, 等. 免疫調節治療對老年心力衰竭患者心功能及淋巴細胞亞群的影響. 中華心血管病雜志, 2010, 38(8): 734-738.
161.	吳朝暉, 袁明遠, 李海苗, 等. 自體外周血干細胞移植治療擴張型心肌病:38例24個月隨訪. 中國組織工程研究與臨床康復, 2010, (1): 121-125.
162.	鐘耀彬, 楊偉民, 周沛曉, 等. 促紅細胞生成素治療慢性心力衰竭合并貧血的臨床研究. 國際醫藥衛生導報, 2013, 19(8): 1133-1135.
163.	張新文, 李三潭, 張源祥, 等. 抗凝治療對心力衰竭患者長期預后的影響研究. 實用心腦肺血管病雜志, 2013, 21(10): 22-24.
164.	余秀瓊, 李錦, 戴玫, 等. 三甲醫院-社區心衰管理模式對心功能的影響研究. 四川醫學, 2014, 35(1): 11-13.
165.	王英. 構建護理防控體系對慢性心力衰竭患者康復的療效觀察. 中國實用醫藥, 2014, 9(28): 195-197.
166.	Balke B. A simple field test for the assessment of physical fitness. CARI Report, 1963, : 63-66.
167.	McGavin CR, Gupta SP, McHardy GJ. Twelve-minute walking test for assessing disability in chronic bronchitis. Br Med J, 1976, 1(6013): 822-823.
168.	Butland RJ, Pang J, Gross ER, et al. Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J (Clin Res Ed), 1982, 284(6329): 1607-1608.
169.	Chrystyn H, Mulley BA, Peake MD. Dose response relation to oral theophylline in severe chronic obstructive airways disease. BMJ, 1988, 297(6662): 1506-1510.
170.	Grove A, Lipworth BJ, Ingram CG, et al. A comparison of the effects of prednisolone and mianserin on ventilatory, exercise and psychometric parameters in patients with chronic obstructive pulmonary disease. Eur J Clin Pharmacol, 1995, 48(1): 13-18.
171.	Langenfeld H, Schneider B, Grimm W, et al. The six-minute walk--an adequate exercise test for pacemaker patients? Pacing Clin Electrophysiol, 1990, 13(12 Pt 2): 1761-1765.
172.	Wang X, Hou Y, Mao J, et al. Western medication plus Traditional Chinese Medicine preparations in patients with chronic heart failure: a prospective, single-blind, randomized, controlled, and multicenter clinical trial. J Tradit Chin Med, 2017, 37(6): 756-766.

1. European Society of Cardiology. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J, 2016: 1-85.
2. Lalonde F. Guidelines for cardiac rehabilitation and secondary prevention programs. J Am Osteopath Assoc NLM, 2012, 11: 753-754.
3. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med, 2002, 166(1): 111-117.
4. Cahalin L, Pappagianopoulos P, Prevost S, et al. The relationship of the 6-min walk test to maximal oxygen consumption in transplant candidates with end-stage lung disease. Chest, 1995, 108(2): 452-459.
5. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation, 2013, 128(16): 240-327.
6. McMurray JJV, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Eur Heart J, 2012, 33(14): 1787-1847.
7. 徐勇勇. 醫學統計學(第2版). 北京: 高等教育出版社, 2004: 234-236.
8. Bristow MR, O'Connell JB, Gilbert EM, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. Circulation, 1994, 89(4): 1632-1642.
9. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation, 1995, 92(2): 212-218.
10. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation, 1995, 92(6): 1499-1506.
11. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective randomized evaluation of carvedilol on symptoms and exercise. Circulation, 1996, 94(11): 2793-2799.
12. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation, 1996, 94(11): 2807-2816.
13. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet, 1997, 349(9049): 375-380.
14. Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure. J Card Fail, 1997, 3(3): 173-179.
15. Khand AU, Rankin AC, Martin W, et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol, 2003, 42(11): 1944-1951.
16. Sanderson JE, Chan SK, Yip G, et al. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol, 1999, 34(5): 1522-1528.
17. Metra M, Giubbini R, Nodari S, et al. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation, 2000, 102(5): 546-551.
18. Sanderson JE, Chan SK, Yu CM, et al. Beta blockers in heart failure: a comparison of a vasodilating beta blocker with metoprolol. Heart, 1998, 79(1): 86-92.
19. Genth-Zotz S, Zotz RJ, Sigmund M, et al. MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing. Eur J Heart Fail, 2000, 2(2): 175-181.
20. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation, 2000, 101(4): 378-384.
21. Beanlands RS, Nahmias C, Gordon E, et al. The effects of beta(1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: A double-blind, placebo-controlled, positron-emission tomography study. Circulation, 2000, 102(17): 2070-2075.
22. de Milliano PA, de Groot AC, Tijssen JG, et al. Beneficial effects of metoprolol on myocardial sympathetic function: Evidence from a randomized, placebo-controlled study in patients with congestive heart failure. Am Heart J, 2002, 144(2): E3.
23. 包志宏, 韓盈, 盛梓松. 充血性心力衰竭患者心功能及運動耐量與卡維地洛的干預. 中國臨床康復, 2005, (15): 53-55.
24. 黃良順, 劉克強. 比較卡維地洛與酒石酸美托洛爾治療慢性心力衰竭的療效. 中外健康文摘, 2013, 29: 89-90.
25. Barabino A, Galbariggi G, Pizzorni C, et al. Comparative effects of long-term therapy with captopril and ibopamine in chronic congestive heart failure in old patients. Cardiology, 1991, 78(3): 243-256.
26. Cowley AJ, McEntegart DJ, Hampton JR, et al. Long-term evaluation of treatment for chronic heart failure: a 1 year comparative trial of flosequinan and captopril. Cardiovasc Drugs Ther, 1994, 8(6): 829-836.
27. Comparison of the effects of cilazapril and captopril versus placebo on exercise testing in chronic heart failure patients: a double-blind, randomized, multicenter trial. Cardiology, 1995, 86(supply 1): 34-40.
28. Beynon JH, Pathy MS. An open, parallel group comparison of quinapril and captopril, when added to diuretic therapy, in the treatment of elderly patients with heart failure. Curr Med Res Opin, 1997, 13(10): 583-592.
29. Hutcheon SD, Gillespie ND, Crombie IK, et al. Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: a randomised double blind placebo controlled trial. Heart, 2002, 88(4): 373-377.
30. Zi M, Carmichael N, Lye M. The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovasc Drugs Ther, 2003, 17(2): 133-139.
31. Kitzman DW, Hundley WG, Brubaker PH, et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circ Heart Fail, 2010, 3(4): 477-485.
32. Dickstein K, Chang P, Willenheimer R, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol, 1995, 26(2): 438-445.
33. Lang RM, Elkayam U, Yellen LG, et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. J Am Coll Cardiol, 1997, 30(4): 983-991.
34. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation, 1999, 100(10): 1056-1064.
35. Granger CB, Ertl G, Kuch J, et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J, 2000, 139(4): 609-617.
36. Willenheimer R, Helmers C, Pantev E, et al. Safety and efficacy of valsartan versus enalapril in heart failure patients. Int J Cardiol, 2002, 85(2-3): 261-270.
37. 李旭豐, 崔紅玉, 楊靜. 纈沙坦治療慢性充血性心力衰竭療效觀察. 中國心血管雜志, 2002, 7(1): 41-43.
38. 黃祖敏, 梁昌強, 王瑞烈, 等. 厄貝沙坦對缺血性心肌病伴慢性心功不全患者六分鐘步行試驗的影響. 遵義醫學院學報, 2004, (5): 464-465.
39. 李漢成. 貝那普利治療慢性充血性心力衰竭療效觀察. 中國熱帶醫學, 2008, (10): 1770-1774.
40. 施亞明, 宗永忠, 紀敏, 等. 纈沙坦和貝那普利對糖尿病心肌病患者六分鐘步行試驗的影響. 臨床醫學, 2009, (12): 11-12.
41. Kurrelmeyer KM, Ashton Y, Xu J, et al. Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. J Card Fail, 2014, 20(8): 560-568.
42. Van Kraaij DJ, Jansen RW, Bouwels LH, et al. Furosemide withdrawal in elderly heart failure patients with preserved left ventricular systolic function. Am J Cardiol, 2000, 85(12): 1461-1466.
43. 賈芳, 黃銳, 鄭僑克, 等. 托拉塞米與呋塞米治療老年慢性心力衰竭伴利尿劑抵抗的短期療效觀察. 中國傷殘醫學, 2013, 21(10): 33-35.
44. Guyatt GH, Sullivan MJ, Fallen EL, et al. A controlled trial of digoxin in congestive heart failure. Am J Cardiol, 1988, 61(4): 371-375.
45. Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol, 1993, 22(4): 955-962.
46. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med, 1993, 329(1): 1-7.
47. Lader E, Egan D, Hunsberger S, et al. The effect of digoxin on the quality of life in patients with heart failure. J Card Fail, 2003, 9(1): 4-12.
48. Benatar D, Hall V, Reddy S, et al. Clinical and neurohormonal effects of nicardipine hydrochloride in patients with severe chronic heart failure receiving angiotensin-converting enzyme inhibitor therapy. Am J Ther, 1998, 5(1): 25-32.
49. Udelson JE, DeAbate CA, Berk M, et al. Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. Am Heart J, 2000, 139(3): 503-510.
50. 肖杰, 顧曄, 成忠, 等. 維拉帕米對左室舒張期心力衰竭患者的療效觀察. 中國醫院藥學雜志, 2010, (16): 1377-1379.
51. Laufs U, Wassmann S, Schackmann S, et al. Beneficial effects of statins in patients with non-ischemic heart failure. Z Kardiol, 2004, 93(2): 103-108.
52. 李繼遠. 辛伐他汀對慢性心力衰竭患者心功能和運動耐量的影響. 實用全科醫學, 2007, (10): 869-870.
53. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med, 2001, 344(12): 873-880.
54. Auricchio A, Stellbrink C, Sack S, et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol, 2002, 39(12): 2026-2033.
55. Leclercq C, Walker S, Linde C, et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J, 2002, 23(22): 1780-1787.
56. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med, 2002, 346(24): 1845-1853.
57. Varma C, Sharma S, Firoozi S, et al. Atriobiventricular pacing improves exercise capacity in patients with heart failure and intraventricular conduction delay. J Am Coll Cardiol, 2003, 41(4): 582-588.
58. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA, 2003, 289(20): 2685-2694.
59. Garrigue S, Bordachar P, Reuter S, et al. Comparison of permanent left ventricular and biventricular pacing in patients with heart failure and chronic atrial fibrillation: a prospective hemodynamic study. Card Electrophysiol Rev, 2003, 7(4): 315-324.
60. Auricchio A, Stellbrink C, Butter C, et al. Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. J Am Coll Cardiol, 2003, 42(12): 2109-2116.
61. Higgins SL, Hummel JD, Niazi IK, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol, 2003, 42(8): 1454-1459.
62. Abraham WT, Young JB, León AR, et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation, 2004, 110(18): 2864-2868.
63. Gasparini M, Bocchiardo M, Lunati M, et al. Comparison of 1-year effects of left ventricular and biventricular pacing in patients with heart failure who have ventricular arrhythmias and left bundle-branch block: the Bi vs Left Ventricular Pacing: an International Pilot Evaluation on Heart Failure Patients with Ventricular Arrhythmias (BELIEVE) multicenter prospective randomized pilot study. Am Heart J, 2006, 152(1): 155. e1-e7.
64. Chung ES, Menon SG, Weiss R, et al. Feasibility of biventricular pacing in patients with recent myocardial infarction: impact on ventricular remodeling. Congest Heart Fail, 2007, 13(1): 9-15.
65. Rao K, Fisher ML, Robinson S, et al. Effect of chronic changes in heart rate on congestive heart failure. J Card Fail, 2007, 13(4): 269-274.
66. Goscinska-Bis K, Bis J, Krejca M, et al. Totally epicardial cardiac resynchronization therapy system implantation in patients with heart failure undergoing CABG. Eur J Heart Fail, 2008, 10(5): 498-506.
67. Orlov MV, Gardin JM, Slawsky M, et al. Biventricular pacing improves cardiac function and prevents further left atrial remodeling in patients with symptomatic atrial fibrillation after atrioventricular node ablation. Am Heart J, 2010, 159(2): 264-270.
68. Sims DB, Mignatti A, Colombo PC, et al. Rate responsive pacing using cardiac resynchronization therapy in patients with chronotropic incompetence and chronic heart failure. Europace, 2011, 13(10): 1459-1463.
69. Thibault B, Ducharme A, Harel F, et al. Left ventricular versus simultaneous biventricular pacing in patients with heart failure and a QRS complex≥120 milliseconds. Circulation, 2011, 124(25): 2874-2881.
70. Di Molfetta A, Forleo GB, Santini L, et al. A novel methodology for AV and VV delay optimization in CRT: results from a randomized pilot clinical trial. J Artif Organs, 2013, 16(3): 273-283.
71. Rampengan SH, Prihartono J, Siagian M, et al. The effect of enhanced external counterpulsation therapy and improvement of functional capacity in chronic heart failure patients: a randomized clinical trial. Acta Med Indones, 2015, 47(4): 275-282.
72. Meyer K, Schwaibold M, Westbrook S, et al. Effects of exercise training and activity restriction on 6-minute walking test performance in patients with chronic heart failure. Am Heart J, 1997, 133(4): 447-453.
73. McKelvie RS, Teo KK, Roberts R, et al. Effects of exercise training in patients with heart failure: the Exercise Rehabilitation Trial (EXERT). Am Heart J, 2002, 144(1): 23-30.
74. Giannuzzi P, Temporelli PL, Corrà U, et al. Antiremodeling effect of long-term exercise training in patients with stable chronic heart failure: results of the Exercise in Left Ventricular Dysfunction and Chronic Heart Failure (ELVD-CHF) Trial. Circulation, 2003, 108(5): 554-559.
75. Gary RA, Sueta CA, Dougherty M, et al. Home-based exercise improves functional performance and quality of life in women with diastolic heart failure. Heart Lung, 2004, 33(4): 210-218.
76. Corvera-Tindel T, Doering LV, Woo MA, et al. Effects of a home walking exercise program on functional status and symptoms in heart failure. Am Heart J, 2004, 147(2): 339-346.
77. 成蓓, 張秀娥, 彭雯. 運動訓練方案對慢性心力衰竭患者運動耐量和心功能的影響(英文). 中國臨床康復, 2005, 9(23): 241-243.
78. Brodie DA, Inoue A. Motivational interviewing to promote physical activity for people with chronic heart failure. J Adv Nurs, 2005, 50(5): 518-527.
79. Oka RK, Sanders MG. The impact of exercise on body composition and nutritional intake in patients with heart failure. Prog Cardiovasc Nurs, 2005, 20(4): 148-154.
80. Dracup K, Evangelista LS, Hamilton MA, et al. Effects of a home-based exercise program on clinical outcomes in heart failure. Am Heart J, 2007, 154(5): 877-883.
81. Witham MD, Argo IS, Johnston DW, et al. Long-term follow-up of very old heart failure patients enrolled in a trial of exercise training. Am J Geriatr Cardiol, 2007, 16(4): 243-248.
82. Karavidas A, Parissis J, Arapi S, et al. Effects of functional electrical stimulation on quality of life and emotional stress in patients with chronic heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy: a randomised, placebo-controlled trial. Eur J Heart Fail, 2008, 10(7): 709-713.
83. Butterfield JA, Faddy SC, Davidson P, et al. Exercise training in patients with stable chronic heart failure: effects on thoracic impedance cardiography and B-type natriuretic peptide. J Cardiopulm Rehabil Prev, 2008, 28(1): 33-37.
84. Nilsson BB, Westheim A, Risberg MA. Effects of group-based high-intensity aerobic interval training in patients with chronic heart failure. Am J Cardiol, 2008, 102(10): 1361-1365.
85. Palevo G, Keteyian SJ, Kang M, et al. Resistance exercise training improves heart function and physical fitness in stable patients with heart failure. J Cardiopulm Rehabil Prev, 2009, 29(5): 294-298.
86. Winkelmann ER, Chiappa GR, Lima CO, et al. Addition of inspiratory muscle training to aerobic training improves cardiorespiratory responses to exercise in patients with heart failure and inspiratory muscle weakness. Am Heart J, 2009, 158(5): 768. e1-e7.
87. Brubaker PH, Moore JB, Stewart KP, et al. Endurance exercise training in older patients with heart failure: results from a randomized, controlled, single-blind trial. J Am Geriatr Soc, 2009, 57(11): 1982-1989.
88. Karapolat H, Demir E, Bozkaya YT, et al. Comparison of hospital-based versus home-based exercise training in patients with heart failure: effects on functional capacity, quality of life, psychological symptoms, and hemodynamic parameters. Clin Res Cardiol, 2009, 98(10): 635-642.
89. Nilsson BB, Westheim A, Risberg MA, et al. No effect of group-based aerobic interval training on N-terminal pro- B-type natriuretic peptide levels in patients with chronic heart failure. Scand Cardiovasc J, 2010, 44(4): 223-229.
90. Caminiti G, Volterrani M, Marazzi G, et al. Tai chi enhances the effects of endurance training in the rehabilitation of elderly patients with chronic heart failure. Rehabil Res Pract, 2011, 2011: 761958.
91. Yeh GY, McCarthy EP, Wayne PM, et al. Tai chi exercise in patients with chronic heart failure: a randomized clinical trial. Arch Intern Med, 2011, 171(8): 750-757.
92. Keast ML, Slovinec D'Angelo ME, Nelson CR, et al. Randomized trial of Nordic walking in patients with moderate to severe heart failure. Can J Cardiol, 2013, 29(11): 1470-1476.
93. Borland M, Rosenkvist A, Cider. A group-based exercise programme did not improve physical activity in patients with chronic heart failure and comorbidity:a randomized controlled trial. J Rehabil Med, 2014, 46: 461-67.
94. Palau P, Domínguez E, Nú?ez E, et al. Effects of inspiratory muscle training in patients with heart failure with preserved ejection fraction. Eur J Prev Cardiol, 2014, 21(12): 1465-1473.
95. Piotrowicz E, Zieliński T, Bodalski R, et al. Home-based telemonitored Nordic walking training is well accepted, safe, effective and has high adherence among heart failure patients, including those with cardiovascular implantable electronic devices: a randomised controlled study. Eur J Prev Cardiol, 2015, 22(11): 1368-1377.
96. Vordos Z, Kouidi E, Mavrovouniotis F, et al. Impact of traditional Greek dancing on jumping ability, muscular strength and lower limb endurance in cardiac rehabilitation programmes. Eur J Cardiovasc Nurs, 2017, 16(2): 150-156.
97. Antonicelli R, Spazzafumo L, Scalvini S, et al. Exercise: a "new drug" for elderly patients with chronic heart failure. Aging (Albany NY), 2016, 8(5): 860-872.
98. 彭雯, 張秀娥, 成蓓. 6分鐘步行試驗在老年慢性心衰患者康復中的應用. 中國康復醫學雜志, 2003, 18(4): 32-34.
99. 趙孝君. 運動訓練改善老年慢性心力衰竭患者的心功能和運動耐力. 中國臨床康復, 2005, (16): 170-171.
100. Li X, Zhang J, Huang J, et al. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. J Am Coll Cardiol, 2013, 62(12): 1065-1072.
101. 何柳平, 吳玉付. 芪參益氣滴丸治療慢性充血性心力衰竭竇性心律震蕩的臨床研究. 天津中醫藥, 2009, 26(3): 202-204.
102. 安炎霞, 張群生, 丁智曉. 芪參益氣滴丸治療冠心病心力衰竭的臨床觀察. 實用心腦肺血管病雜志, 2010, (3): 367-368.
103. 陳協興, 葉明芳. 燈盞生脈膠囊對慢性心力衰竭患者心功能及運動耐量的影響. 中外婦兒健康, 2011, (8): 286.
104. 何懷陽, 容超. 固本救心方治療男性重癥心力衰竭的臨床研究及對血清睪酮的影響. 時珍國醫國藥, 2013, 24(4): 835-836.
105. 王永剛, 鐘偉, 于遠望, 等. 參附芎澤膠囊治療慢性心力衰竭59例臨床觀察. 中醫雜志, 2013, 54(3): 218-221.
106. 袁萌楠, 賈銀明. 芪藶強心膠囊治療慢性心力衰竭療效觀察. 廣西中醫藥, 2014, 37(5): 12-14.
107. Sueta CA, Gheorghiade M, Adams KF Jr, et al. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group. Am J Cardiol, 1995, 75(3): 34A-43A.
108. Rector TS, Bank AJ, Mullen KA, et al. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation, 1996, 93(12): 2135-2141.
109. Osterziel KJ, Strohm O, Schuler J, et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet, 1998, 351(9111): 1233-1237.
110. Oliva F, Latini R, Politi A, et al. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J, 1999, 138(2 Pt 1): 247-253.
111. Deswal A, Bozkurt B, Seta Y, et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation, 1999, 99(25): 3224-3226.
112. Artinian NT, Harden JK, Kronenberg MW, et al. Pilot study of a Web-based compliance monitoring device for patients with congestive heart failure. Heart Lung, 2003, 32(4): 226-233.
113. Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation, 2003, 107(2): 294-299.
114. Zeng XH, Zeng XJ, Li YY. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol, 2003, 92(2): 173-176.
115. Galbreath AD, Krasuski RA, Smith B, et al. Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure. Circulation, 2004, 110(23): 3518-3526.
116. Witte KK, Nikitin NP, Parker AC, et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J, 2005, 26(21): 2238-2244.
117. Torre-Amione G, Sestier F, Radovancevic B, et al. Broad modulation of tissue responses (immune activation) by celacade may favorably influence pathologic processes associated with heart failure progression. Am J Cardiol, 2005, 95(11A): 30C-37C.
118. Gong K, Zhang Z, Sun X, et al. The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure. Am Heart J, 2006, 151(1): 62-68.
119. Gavin AD, Struthers AD. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart, 2005, 91(6): 749-753.
120. Bradley TD, Logan AG, Kimoff RJ, et al. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med, 2005, 353(19): 2025-2033.
121. Beck-da-Silva L, Higginson L, Fraser M, et al. Effect of Orlistat in obese patients with heart failure: a pilot study. Congest Heart Fail, 2005, 11(3): 118-123.
122. Palazzuoli A, Silverberg D, Iovine F, et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J, 2006, 152(6): 1096.
123. Cingolani HE, Plastino JA, Escudero EM, et al. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study. J Card Fail, 2006, 12(7): 491-498.
124. Neelagaru SB, Sanchez JE, Lau SK, et al. Nonexcitatory, cardiac contractility modulation electrical impulses: feasibility study for advanced heart failure in patients with normal QRS duration. Heart Rhythm, 2006, 3(10): 1140-1147.
125. Jug B, Sebestjen M, Sabovic M, et al. Clopidogrel is associated with a lesser increase in NT-proBNP when compared to aspirin in patients with ischemic heart failure. J Card Fail, 2006, 12(6): 446-451.
126. Kumar A, Singh RB, Saxena M, et al. Effect of carni Q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the Tishcon study. Acta Cardiol, 2007, 62(4): 349-354.
127. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation, 2007, 116(14): 1555-1562.
128. Di Napoli P, Di Giovanni P, Gaeta MA, et al. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial. J Cardiovasc Pharmacol, 2007, 50(5): 585-589.
129. Kourea K, Parissis JT, Farmakis D, et al. Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil, 2008, 15(3): 365-369.
130. Parissis JT, Kourea K, Panou F, et al. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J, 2008, 155(4): 751. e1-e7.
131. Khan MN, Ja?s P, Cummings J, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med, 2008, 359(17): 1778-1785.
132. Bakan G, Akyol AD. Theory-guided interventions for adaptation to heart failure. J Adv Nurs, 2008, 61(6): 596-608.
133. Kanoksilp A, Hengrussamee K, Wuthiwaropas P. A comparison of one-year outcome in adult patients with heart failure in two medical setting: heart failure clinic and daily physician practice. J Med Assoc Thai, 2009, 92(4): 466-470.
134. Moreira DM, Vieira JL, Gottschall CA. The effects of METhotrexate therapy on the physical capacity of patients with ISchemic heart failure: a randomized double-blind, placebo-controlled trial (METIS trial). J Card Fail, 2009, 15(10): 828-834.
135. Evangelista LS, Heber D, Li Z, et al. Reduced body weight and adiposity with a high-protein diet improves functional status, lipid profiles, glycemic control, and quality of life in patients with heart failure: a feasibility study. J Cardiovasc Nurs, 2009, 24(3): 207-215.
136. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med, 2009, 361(25): 2436-2448.
137. Shelton RJ, Clark AL, Goode K, et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart, 2009, 95(11): 924-930.
138. Swanson KS, Gevirtz RN, Brown M, et al. The effect of biofeedback on function in patients with heart failure. Appl Psychophysiol Biofeedback, 2009, 34(2): 71-91.
139. Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol, 2009, 54(10): 919-927.
140. Iellamo F, Volterrani M, Caminiti G, et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol, 2010, 56(16): 1310-1316.
141. Witham MD, Crighton LJ, Gillespie ND, et al. The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: a randomized controlled trial. Circ Heart Fail, 2010, 3(2): 195-201.
142. Giles TD, Elkayam U, Bhattacharya M, et al. Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease. Congest Heart Fail, 2010, 16(3): 111-117.
143. Povsic TJ, O'Connor CM, Henry T, et al. A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction. Am Heart J, 2011, 162(4): 654-662.
144. Duckers HJ, Houtgraaf J, Hehrlein C, et al. Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial. EuroIntervention, 2011, 6(7): 805-812.
145. Caminiti G, Volterrani M, Marazzi G, et al. Hydrotherapy added to endurance training versus endurance training alone in elderly patients with chronic heart failure: a randomized pilot study. Int J Cardiol, 2011, 148(2): 199-203.
146. Carvalho AP, Rassi S, Fontana KE, et al. Influence of creatine supplementation on the functional capacity of patients with heart failure. Arq Bras Cardiol, 2012, 99(1): 623-629.
147. Costanzo MR, Heywood JT, Massie BM, et al. A double-blind, randomized, parallel, placebo-controlled study examining the effect of cross-linked polyelectrolyte in heart failure patients with chronic kidney disease. Eur J Heart Fail, 2012, 14(8): 922-930.
148. Bussoni MF, Guirado GN, Matsubara LS, et al. Diastolic function and functional capacity after a single session of continuous positive airway pressure in patients with compensated heart failure. Clinics (Sao Paulo), 2014, 69(5): 354-359.
149. Vullaganti S, Goldsmith J, Teruya S, et al. Cardiovascular effects of hemoglobin response in patients receiving epoetin alfa and oral iron in heart failure with a preserved ejection fraction. J Geriatr Cardiol, 2014, 11(2): 100-105.
150. Winter JL, Castro PF, Quintana JC, et al. Effects of trimetazidine in non-ischemic heart failure: A randomized study. J Card Fail, 2014, 20(3): 149-154.
151. Dunbar SB, Reilly CM, Gary R, et al. Randomized clinical trial of an integrated self-care intervention for persons with heart failure and diabetes: quality of life and physical functioning outcomes. J Card Fail, 2015, 21(9): 719-729.
152. Athilingam P, Edwards JD, Valdes EG, et al. Computerized auditory cognitive training to improve cognition and functional outcomes in patients with heart failure: Results of a pilot study. Heart Lung, 2015, 44(2): 120-128.
153. Anker SD, Coats AJ, Cristian G, et al. A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial). Eur Heart J, 2015, 36(34): 2297-2309.
154. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J, 2015, 36(11): 657-668.
155. van Riet EE, Hoes AW, Limburg A, et al. Effect of training general practitioners in drug treatment of newly detected heart failure patients with reduced or preserved ejection fraction: A cluster randomized trial. Int J Cardiol, 2016, 217: 174-182.
156. Maulik SK, Wilson V, Seth S, et al. Clinical efficacy of water extract of stem bark of Terminalia arjuna (Roxb. ex DC.) Wight & Arn. in patients of chronic heart failure: a double-blind, randomized controlled trial. Phytomedicine, 2016, 23(11): 1211-1219.
157. Domenichini G, Rahneva T, Diab IG, et al. The lung impedance monitoring in treatment of chronic heart failure (the LIMIT-CHF study). Europace, 2016, 18(3): 428-435.
158. Bublitz C, Renno AC, Ramos RS, et al. Acute effects of low-level laser therapy irradiation on blood lactate and muscle fatigue perception in hospitalized patients with heart failure-a pilot study. Lasers Med Sci, 2016, 31(6): 1203-1209.
159. 李兢, 莊漢屏, 劉麗華. 曲美他嗪輔助治療老年人充血性心力衰竭的臨床觀察. 實用心腦肺血管病雜志, 2004, 12(3): 129-132.
160. 曹曉菁, 李艷芳, 曹芳芳, 等. 免疫調節治療對老年心力衰竭患者心功能及淋巴細胞亞群的影響. 中華心血管病雜志, 2010, 38(8): 734-738.
161. 吳朝暉, 袁明遠, 李海苗, 等. 自體外周血干細胞移植治療擴張型心肌病:38例24個月隨訪. 中國組織工程研究與臨床康復, 2010, (1): 121-125.
162. 鐘耀彬, 楊偉民, 周沛曉, 等. 促紅細胞生成素治療慢性心力衰竭合并貧血的臨床研究. 國際醫藥衛生導報, 2013, 19(8): 1133-1135.
163. 張新文, 李三潭, 張源祥, 等. 抗凝治療對心力衰竭患者長期預后的影響研究. 實用心腦肺血管病雜志, 2013, 21(10): 22-24.
164. 余秀瓊, 李錦, 戴玫, 等. 三甲醫院-社區心衰管理模式對心功能的影響研究. 四川醫學, 2014, 35(1): 11-13.
165. 王英. 構建護理防控體系對慢性心力衰竭患者康復的療效觀察. 中國實用醫藥, 2014, 9(28): 195-197.
166. Balke B. A simple field test for the assessment of physical fitness. CARI Report, 1963, : 63-66.
167. McGavin CR, Gupta SP, McHardy GJ. Twelve-minute walking test for assessing disability in chronic bronchitis. Br Med J, 1976, 1(6013): 822-823.
168. Butland RJ, Pang J, Gross ER, et al. Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J (Clin Res Ed), 1982, 284(6329): 1607-1608.
169. Chrystyn H, Mulley BA, Peake MD. Dose response relation to oral theophylline in severe chronic obstructive airways disease. BMJ, 1988, 297(6662): 1506-1510.
170. Grove A, Lipworth BJ, Ingram CG, et al. A comparison of the effects of prednisolone and mianserin on ventilatory, exercise and psychometric parameters in patients with chronic obstructive pulmonary disease. Eur J Clin Pharmacol, 1995, 48(1): 13-18.
171. Langenfeld H, Schneider B, Grimm W, et al. The six-minute walk--an adequate exercise test for pacemaker patients? Pacing Clin Electrophysiol, 1990, 13(12 Pt 2): 1761-1765.
172. Wang X, Hou Y, Mao J, et al. Western medication plus Traditional Chinese Medicine preparations in patients with chronic heart failure: a prospective, single-blind, randomized, controlled, and multicenter clinical trial. J Tradit Chin Med, 2017, 37(6): 756-766.

Chinese Journal of Evidence-Based Medicine

The application value of 6-minute walking test in clinical evaluation of chronic heart failure

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content